Síntese e avaliação biológica de bioisósteros de nitrofural ativos contra Leishmania amazonensis

• Ano de defesa: 2015
• Autor(a) principal: Jornada, Daniela Hartmann [UNESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Estadual Paulista (Unesp)
• Palavras-chave em Português: Leishmaniose; Agentes anti-infecciosos; Agentes antivirais; Fármacos; Antiviral agents
• Link de acesso: http://hdl.handle.net/11449/121927

Cutaneous leishmaniasis is a world widely distributed disease and it is estimated, by the World Health Organization (WHO), the incidence of 500,000 to one million cases per year. According to the Department of the Unified Health System (DATASUS), in 2005 it was registered more than 180 million cases of cutaneous leishmaniasis in Brazil. Although treatments for leishmaniasis are available, it is a complex process, because of difficulties in administration, once the majority of the drugs are injectable, the several numbers of adverse effects, and liver, renal and cardiac toxicity. Due to that, the development of more effective and less toxic drugs becomes urgent. The bioisosterism is a molecular modification strategy that aims to obtain new analogues with the same biological activity. It has been used in the research for new drugs, in order to improve the effectiveness and safety in the treatment of various diseases. The nitrofural (NF) 5-nitro-2-furaldehyde semicarbazone, is a drug used as topical antimicrobial in various types of skin lesions is described which has activity against L. donovani, L. enriettii and L. major amastigote forms. Based on the various drug activities, the proposed work aimed the synthesis of bioisosters of nitrofural and evaluation of compounds for in vitro leishmanicidal activity. Were synthesized and characterized via analytical methods eight compounds, one unpublished. Seven of them were evaluated for biological activity against the amastigotesn forms of L. amazonensis by MTT assay (3-methyl bromide [4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide). The Lapdesf-MetSFS (8) compound showed activity comparable to that of pentamidine, standard drug used in therapy.